Display options
Cite
Maher M, Diesch J, Le Pannérer MM, et al. Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18. Sci Rep. 2021;11(1):21145doi: 10.1038/s41598-021-00623-w.
Maher, M., Diesch, J., Le Pannérer, M. M., Cabezón, M., Mallo, M., Vergara, S., Méndez López, A., Mesa Tudel, A., Solé, F., Sorigue, M., Zamora, L., Granada, I., & Buschbeck, M. (2021). Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18. Scientific reports, 11(1), 21145. https://doi.org/10.1038/s41598-021-00623-w
Maher, Michael, et al. "Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18." Scientific reports vol. 11,1 (2021): 21145. doi: https://doi.org/10.1038/s41598-021-00623-w
Maher M, Diesch J, Le Pannérer MM, Cabezón M, Mallo M, Vergara S, Méndez López A, Mesa Tudel A, Solé F, Sorigue M, Zamora L, Granada I, Buschbeck M. Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18. Sci Rep. 2021 Oct 27;11(1):21145. doi: 10.1038/s41598-021-00623-w. PMID: 34707142; PMCID: PMC8551338.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2021 Oct 27;11(1):21145. doi: 10.1038/s41598-021-00623-w.

Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18.

Scientific reports

Michael Maher, Jeannine Diesch, Marguerite-Marie Le Pannérer, Marta Cabezón, Mar Mallo, Sara Vergara, Aleix Méndez López, Alba Mesa Tudel, Francesc Solé, Marc Sorigue, Lurdes Zamora, Isabel Granada, Marcus Buschbeck

Affiliations

  1. Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
  2. Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, 08916, Badalona, Spain.
  3. Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
  4. Microarrays Unit, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
  5. MDS Group, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
  6. Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain. [email protected].
  7. Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, 08916, Badalona, Spain. [email protected].

PMID: 34707142 PMCID: PMC8551338 DOI: 10.1038/s41598-021-00623-w

Abstract

Haematopoietic malignancies are frequently characterized by karyotypic abnormalities. The development of targeted drugs has been pioneered with compounds against gene products of fusion genes caused by chromosomal translocations. While polysomies are equally frequent as translocations, for many of them we are lacking therapeutic approaches aimed at synthetic lethality. Here, we report two new cell lines, named MBU-7 and MBU-8, that differ in complete trisomy of chromosome18, a partial trisomy of chromosome 7 and a tetrasomy of the p-arm of chromosome 8, but otherwise share the same mutational pattern and complex karyotype. Both cell lines are divergent clones of U-937 cells and have the morphology and immunoprofile of monocytic cells. The distinct karyotypic differences between MBU-7 and MBU-8 are associated with a difference in the specific response to nucleoside analogues. Taken together, we propose the MBU-7 and MBU-8 cell lines described here as suitable in vitro models for screening and testing vulnerabilities that are associated with the disease-relevant polysomies of chromosome 7, 8 and 18.

© 2021. The Author(s).

References

  1. Cancer Discov. 2014 Mar;4(3):362-75 - PubMed
  2. Blood. 2010 Nov 18;116(20):4086-94 - PubMed
  3. Nat Rev Drug Discov. 2020 Jan;19(1):23-38 - PubMed
  4. J Biomol Tech. 2018 Jul;29(2):25-38 - PubMed
  5. Cancer Genet Cytogenet. 2005 Aug;161(1):78-81 - PubMed
  6. Leuk Lymphoma. 2018 Feb;59(2):274-287 - PubMed
  7. Curr Treat Options Oncol. 2019 Feb 11;20(2):15 - PubMed
  8. Cytometry B Clin Cytom. 2021 May;100(3):292-295 - PubMed
  9. Leukemia. 2015 Jun;29(6):1290-300 - PubMed
  10. Cancers (Basel). 2021 Apr 06;13(7): - PubMed
  11. Genet Med. 2016 Feb;18(2):128-36 - PubMed
  12. Leukemia. 1997 Dec;11(12):2032-8 - PubMed
  13. Blood. 2015 Jul 2;126(1):9-16 - PubMed
  14. Leuk Lymphoma. 2004 Apr;45(4):639-48 - PubMed
  15. Hemasphere. 2020 Sep 01;4(5):e466 - PubMed
  16. Leukemia. 2017 Oct;31(10):2271-2273 - PubMed
  17. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9 - PubMed
  18. DNA Repair (Amst). 2006 Sep 8;5(9-10):1282-97 - PubMed
  19. FASEB J. 2005 Mar;19(3):434-6 - PubMed
  20. Cytotechnology. 1992;8(1):13-20 - PubMed
  21. Nature. 1994 Nov 10;372(6502):143-9 - PubMed
  22. Blood. 1992 May 1;79(9):2378-83 - PubMed
  23. Nature. 2010 Dec 23;468(7327):1105-9 - PubMed
  24. Cancer Genet Cytogenet. 2002 Sep;137(2):124-32 - PubMed
  25. Mol Cytogenet. 2020 Dec 14;13(1):50 - PubMed
  26. PLoS One. 2011;6(8):e23372 - PubMed
  27. Clin Epigenetics. 2016 Jun 21;8:71 - PubMed
  28. Blood. 2018 Mar 29;131(13):1406-1414 - PubMed
  29. Expert Rev Hematol. 2019 Nov;12(11):947-958 - PubMed
  30. N Engl J Med. 2006 Oct 5;355(14):1456-65 - PubMed
  31. Blood. 2000 Dec 1;96(12):3932-8 - PubMed
  32. J Leukoc Biol. 1985 Apr;37(4):407-22 - PubMed
  33. Int J Cancer. 1976 May 15;17(5):565-77 - PubMed
  34. Pathol Biol (Paris). 2007 Feb;55(1):37-48 - PubMed
  35. Blood Rev. 2004 Jun;18(2):115-36 - PubMed
  36. Blood. 2010 Jul 22;116(3):354-65 - PubMed
  37. Cytogenet Cell Genet. 2001;94(1-2):9-14 - PubMed
  38. Int J Cancer. 2016 Sep 1;139(5):1106-16 - PubMed
  39. Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):328-339 - PubMed
  40. J Mol Diagn. 2013 Mar;15(2):186-95 - PubMed
  41. Blood. 2011 Oct 6;118(14):3803-10 - PubMed
  42. Exp Hematol. 1997 Apr;25(4):312-20 - PubMed
  43. Genes Chromosomes Cancer. 2017 Mar;56(3):243-252 - PubMed
  44. Nature. 2018 Aug;560(7718):325-330 - PubMed
  45. Leukemia. 2008 Nov;22(11):2029-40 - PubMed
  46. Biotechniques. 1993 Jul;15(1):100-19 - PubMed
  47. Blood. 2012 Jun 14;119(24):5824-31 - PubMed
  48. Expert Rev Anticancer Ther. 2003 Oct;3(5):717-28 - PubMed

Publication Types

Grant support